Cargando…
MiR-129-3p promotes docetaxel resistance of breast cancer cells via CP110 inhibition
Docetaxel is commonly used as an effective chemotherapeutic agent in breast cancer treatment, but the underlying mechanisms of drug resistance are not fully understood. The purpose of this study was to investigate the possible role of miR-129-3p in breast cancer cell resistance to docetaxel. MiR-129...
Autores principales: | Zhang, Yuan, Wang, Yu, Wei, Yifang, Li, Mengyang, Yu, Shentong, Ye, Mingxiang, Zhang, Hongmei, Chen, Suning, Liu, Wenchao, Zhang, Jian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4614026/ https://www.ncbi.nlm.nih.gov/pubmed/26487539 http://dx.doi.org/10.1038/srep15424 |
Ejemplares similares
-
miR-129-3p controls centrosome number in metastatic prostate cancer cells by repressing CP110
por: Bijnsdorp, Irene V., et al.
Publicado: (2016) -
miR-34/449 miRNAs are required for motile ciliogenesis by repressing cp110
por: Song, Rui, et al.
Publicado: (2014) -
miR-129-5p Inhibits Bone Formation Through TCF4
por: Yin, Chong, et al.
Publicado: (2020) -
Evaluation of the expressed miR-129 and miR-549a in patients with multiple sclerosis
por: Montazeri, Mina, et al.
Publicado: (2021) -
KSRP specifies monocytic and granulocytic differentiation through regulating miR-129 biogenesis and RUNX1 expression
por: Zhao, Hongmei, et al.
Publicado: (2017)